Free tool
FAERS Monitor: Onapgo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214056 or its brand name (Onapgo, Apomorphine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,686
Serious
1,098
65% of reports
Hospitalization
482
Death reported
102
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea316
- somnolence279
- dizziness225
- dyskinesia219
- fall204
- hallucination164
- fatigue158
- hypotension150
- injection site erythema135
- gait disturbance114
- injection site nodule101
- infusion site erythema99
- vomiting97
- speech disorder94
- constipation88
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 8 |
| 2015 | 10 |
| 2016 | 4 |
| 2017 | 47 |
| 2018 | 387 |
| 2019 | 24 |
| 2020 | 32 |
| 2021 | 32 |
| 2022 | 38 |
| 2023 | 46 |
| 2024 | 76 |
| 2025 | 401 |
| 2026 | 562 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,473 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion site erythemaSignal | 99 | 148.2 | 122.3 | 14,167 |
| injection site noduleSignal | 101 | 115.5 | 95.5 | 11,256 |
| dyskinesiaSignal | 219 | 67.6 | 59.7 | 14,250 |
| hallucinationSignal | 164 | 27.2 | 23.5 | 4,119 |
| speech disorderSignal | 94 | 22.4 | 18.4 | 1,903 |
| somnolenceSignal | 279 | 17.3 | 15.5 | 4,306 |
| injection site erythemaSignal | 135 | 13.6 | 11.6 | 1,570 |
| hypotensionSignal | 150 | 9.3 | 8.0 | 1,118 |
| fallSignal | 204 | 7.7 | 6.7 | 1,191 |
| gait disturbanceSignal | 114 | 7.4 | 6.2 | 634 |
| dizzinessSignal | 225 | 5.6 | 5.0 | 872 |
| constipationSignal | 88 | 5.0 | 4.1 | 283 |
| nauseaSignal | 316 | 5.0 | 4.5 | 1,041 |
| vomitingSignal | 97 | 2.6 | 2.1 | 94 |
| fatigueSignal | 158 | 2.5 | 2.2 | 150 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.